// App-Quantinova.ai

8034 : Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.

Researchers

Presenter

  • Roman Hajek

Principal Investigators

  • Philippe Moreau

  • Bradley Augustson

  • Nelson Castro

  • Tomas Pika

  • Sosana Delimpasi

  • Javier de La Rubia

  • Angelo Maiolino

  • Tony J. Reiman

  • Irina Kryuchkova

  • Joaquin Martinez-Lopez

  • Thomas G. Martin

  • Joseph Mikhael

  • Kwee Yong

  • Marie-Laure Risse

  • Galle Asset

  • Sylvia Marion

  • Meletios A. Dimopoulos

Medical Centers

  • Department of Hemato-Oncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic, Hematology, University Hospital Hotel-Dieu, Nantes, France

  • Sir Charles Gairdner Hospital, Perth, Australia

  • H Cancer de Barretos, Barretos, Brazil

  • Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic, Department of Haematology, General Hospital of Athens, Athens, Greece

  • Pathology Department, University Hospital La Fe, Valencia, Spain

  • Instituto COI de Educacao e Pesquisa, Rio De Janeiro, Brazil

  • Department of Oncology,Saint John Regional Hospital, Dalhousie University and University of New Brunswick,Saint John,Canada

  • Research Institute of Clinical Immunology, Novosibirsk, Russian Federation

  • Departamento de Hematología,Hospital 12 de Octubre, Complutense University, CNIO,Madrid,Spain

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, University College Hospital, London, United Kingdom

  • Sanofi R&D, Vitry-Alfortville, France

  • Sanofi, Chilly-Mazarin, France

  • Sanofi, Cambridge, MA

  • National and Kapodistrian University of Athens, Athens, Greece

Locations

  • France

  • Australia

  • Brazil

  • Greece

  • Spain

  • Canada

  • Russia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved